RFCA
ABUS icon

R&F Capital Advisors’s Arbutus Biopharma ABUS Stock Holding History

R&F Capital Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$38K Buy
+11,547
New +$32K 0.01% 657

Other funds holding ABUS

QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

R&F Capital Advisors's ABUS Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in Arbutus Biopharma (ABUS) in Q1 2017: 11,547 shares worth $38K. The stake represents 0.01% of the portfolio and ranks #657 among its holdings.

53 funds tracked by Wall St. Rank hold ABUS as of Q1 2017.

  • R&F Capital Advisors held 11,547 shares of Arbutus Biopharma worth $38K as of Q1 2017.
  • Arbutus Biopharma was a new R&F Capital Advisors position in Q1 2017.
  • Arbutus Biopharma made up 0.01% of R&F Capital Advisors's portfolio in Q1 2017, its #657 holding.
  • 53 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.